Bonesupport: FDA clearance for trauma indication - Redeye

Redeye embraces the FDA clearance for the trauma indication using CERAMENT G in the US. However, we make no estimate or valuation changes as we already included the indication into our forecasts. Still, we highlight that the clearance is an essential part of its commercialisation, as the company can now market and sell CERAMENT G for trauma cases (though off-label sales from the indication was already being generated). We reiterate our SEK256 base case and judge that the share should see a positive reaction, probably trading up c10% during the day.

Länk till analysen i sin helhet: https://www.redeye.se/research/990481/bonesupport-fda-clearance-for-trauma-indication?utm_source=finwire&utm_medium=RSS